

**ASX RELEASE**

**29 October 2020**

## **QUARTERLY ACTIVITIES AND CASH FLOW REPORTS**

**Melbourne, Australia:** Amplia Therapeutics Ltd (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce further progress across its small molecule, FAK inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 30 September 2020.

### **Key Highlights from the Quarter**

- Received clearance from the Alfred Hospital Human Research Ethics Committee (HREC) to conduct a Phase 1 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945, in healthy volunteers;
- Appointed Dr Mark Devlin as Chief Scientific Officer.
- Completed an Entitlement Offer which raised approximately \$4.0 million at \$0.10 per share

Amplia’s CEO and Managing Director, Dr John Lambert, commented that “Much of what we have worked towards over the last two years has come to fruition during this quarter. Receiving HREC approval to initiate our Phase 1 clinical study and initiation of the trial marks our transition into a clinical stage company. With the trial expected to complete by mid-2021, and a number of non-clinical studies planned or underway to drive our future clinical and partnering programs, we are continuing to build momentum in the Company.”

### **Operations update**

Following completion of the required preclinical safety studies, Amplia requested clearance from an independent ethics committee to conduct its planned Phase 1 trial in healthy volunteers. The proposed protocol was reviewed and approved by the Alfred Hospital Human Research Ethics Committee (HREC), completing the final step required before the trial could commence. On October 8, just after the period covered by this report, the Company announced that the first human subjects had been dosed with AMP945. The Phase 1 trial is being run under contract with Nucleus Network (Melbourne, Australia), and is expected to take 6-9 months to complete.

In August, Amplia appointed Dr Mark Devlin to the role of Chief Scientific Officer. Dr Devlin headed the team that initially discovered and developed the Company’s FAK inhibitor drugs at the Peter MacCallum Cancer Centre as part of the CRC for Cancer Therapeutics. Most recently, Dr Devlin was Chief Executive Officer of CTxONE, a commercial development partner for the Cancer Therapeutics. He holds a PhD in Pharmacology from the University of Melbourne, a Graduate Diploma in Drug Development from the University of New South Wales and an MBA from Melbourne Business School.

During the quarter, Amplia completed a fully underwritten, accelerated, pro rata, non-renounceable entitlement offer issuing approximately 39.9 million new fully paid ordinary shares at \$0.10 per share, to raise approximately \$4.0 million before costs. The proceeds from the capital raising are being used to fund the Company’s Phase 1 clinical trial of AMP945, additional nonclinical studies, and provide the Company with necessary working capital.

**Financial update**

Amplia finished the September 2020 quarter with cash of \$3,765,000. During the quarter, the Company used \$523,000 in operating activities, with \$294,000 being used for research and development that was primarily focused on completing studies to support the Phase 1 clinical trial of AMP945.

During the quarter the Company completed a fully underwritten, accelerated, non-renounceable Entitlement Offer to raise \$4.0M before costs. The institutional component of the Entitlement Offer raised \$2.0M and was strongly supported by the Company's largest shareholder, Platinum Investment Management Limited which increased its holding to 16.0%. In addition, Amplia welcomed Blueflag Holdings Pty Ltd onto its register. Blueflag now holds 7.0% of the Company.

**Payments to Related Entities**

In Section 6.1 of the Appendix 4C lodged for this quarter, the Company discloses salary and superannuation payments of \$49,275 to the CEO/Managing Director in line with Dr Lambert's employment contract as well as \$17,500 in Director fee payments.

**Outlook and future activities**

Amplia's primary focus for the remainder of 2020 is the execution of its Phase 1 clinical trial of AMP945. In addition, the Company is undertaking a parallel program of non-clinical studies for AMP945 and AMP886 that will inform the Company's planned Phase 2 program, currently scheduled to commence in late 2021, and assist the company in potential partnering discussions around other applications for its proprietary FAK inhibitors .

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

**For Further Information**

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Amplia Therapeutics Limited

**ABN**

16 165 160 841

**Quarter ended ("current quarter")**

30 September 2020

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	<294>	<557>
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	<107>	<208>
(f) administration and corporate costs	<130>	<193>
1.3 Dividends received (see note 3)		
1.4 Interest received	-	1
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	-	34
1.8 Other (provide details if material)		
Intellectual property costs & licence fees	<2>	<30>
Covid cashflow boost	43	43
Miscellaneous	<33>	<29>
<b>1.9 Net cash from / (used in) operating activities</b>	<b>&lt;523&gt;</b>	<b>&lt;939&gt;</b>

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	-	-
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,988	3,988
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	<392>	<392>
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>3,596</b>	<b>3,596</b>

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	691	1,108
4.2	Net cash from / (used in) operating activities (item 1.9 above)	<523>	<939>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,596	3,596
4.5	Effect of movement in exchange rates on cash held	1	-
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>3,765</b>	<b>3,765</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	110	37
5.2	Call deposits	3,655	654
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,765</b>	<b>691</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1.2	67
6.2	Aggregate amount of payments to related parties and their associates included in item 2.3	-
Item 6.1 are total payments of \$49,275 to the CEO/Managing Director as salary and superannuation and Director fee payments of \$17,500.		

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

**7. Financing facilities**

*Note: the term "facility" includes all forms of financing arrangements available to the entity.*

*Add notes as necessary for an understanding of the sources of finance available to the entity.*

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
	-	-

7.5 **Unused financing facilities available at quarter end**

-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (Item 1.9)	<523>
8.2 Cash and cash equivalents at quarter end (Item 4.6)	3,765
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	3,765
8.5 <b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	7.20

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

- Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

- Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 October 2020

Authorised by: John Lambert – Chief Executive Officer  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.